peptide analogue comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-10-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。
Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。
| Property | Value | Notes |
|---|---|---|
| Chemical class | GLP-1 receptor agonist peptide | Mimics endogenous incretin signaling |
| Molecular mass | Approximately 4114 Da | Modified 31-amino-acid backbone |
| Appearance | White to off-white powder | Typical of lyophilized peptide material |
| Solubility | Soluble in water | Behavior depends on salt form and buffer |
| Elimination half-life | About one week | Supported by albumin binding and protease resistance |
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
=== Bolus shape === An insulin pump user can influence the profile of the rapid-acting insulin by shaping the bolus. Users can experiment with bolus shapes to determine what is best for any given food, which means that they can improve control of blood sugar by adapting the bolus shape to their needs. A standard bolus is an infusion of insulin pumped completely at the onset of the bolus. It's the most similar to an injection. By pumping with a "spike" shape, the expected action is the fastest possible bolus for that type of insulin. The standard bolus is most appropriate when eating high carb, low protein, low fat meals because it will return blood sugar to normal levels quickly. An extended bolus is a slow infusion of insulin spread out over time. By pumping with a "square wave" shape, the bolus avoids a high initial dose of insulin that may enter the blood and cause low blood sugar before digestion can facilitate sugar entering the blood. The extended bolus also extends the action of insulin well beyond that of the insulin alone. The extended bolus is appropriate when covering high fat high protein meals such as steak, which will be raising blood sugar for many hours past the onset of the bolus. The extended bolus is also useful for those with slow digestion (such as with gastroparesis or coeliac disease). A combination bolus/multiwave bolus is the combination of a standard bolus spike with an extended bolus square wave. This shape provides a large dose of insulin up front, and then also extends the tail of the insulin action.
== Features == Copper-catalyzed allylic substitutions are characterized by their unique regioselectivity compared to other transition-metal-catalyzed allylic substitutions, the most well-known being the palladium-catalyzed Tsuji-Trost reaction. The distinct mechanism of copper-catalyzed allylic substitutions has been known to provide high regioselectivity of the γ substituted product, compared to the α substituted isomer. The copper catalyst used can be symmetrical with two identical R groups, or with two different ligands. These reactions typically utilize “hard” carbon nucleophiles such as Grignard, diorganozinc, organolithium, and trialkyl aluminum reagents. This contrasts palladium-catalyzed allylic substitutions which involve “soft” nucleophiles..
Muscle fatigue may be due to problems with the nerve supply, neuromuscular disease (such as myasthenia gravis), inborn errors of metabolism (such as metabolic myopathies), or problems with muscle itself. The latter category includes polymyositis and other muscle disorders.
The Umayyad Caliphate ruled al-Andalus as a province until its independence in 756 under the Emirate of Córdoba, which in 929 gave way to a caliphate that lasted until it fragmented into states known as taifas, collapsing in 1031, and most of what is now central and southern Portugal falling under the Taifa of Badajoz. The taifas were conquered by Muslim forces from North Africa, first completely by the Almoravids by 1115, who were in turn followed by the Almohads in the 1140s. Northern incursions also occurred during this period, with Viking raids recorded from 844 into the 11th century.
Sources: en.wikipedia.org
The Official Handbook of the Marvel Universe A to Z, Vol. 5, published in 2008, originally designated the Marvel Cinematic Universe as Earth-199999 within the continuity of Marvel's comic multiverse, a collection of fictional alternate universes, although, this designation was rarely used officially outside of the source material. The television series Loki and What If...? were the first to explore the concept of the multiverse within the MCU, as well as the film Spider-Man: No Way Home, which connected the MCU to other Spider-Man film franchises by featuring characters from Sam Raimi's Spider-Man trilogy (2002–2007), Marc Webb's The Amazing Spider-Man films (2012–14), and Sony's Spider-Man Universe (SSU). The SSU film Venom: Let There Be Carnage (2021) briefly featured the main universe of the MCU as well. In Doctor Strange in the Multiverse of Madness, the main universe of MCU events was designated as Earth-616 (a designation first referenced in Spider-Man: Far From Home), sharing the name of the main Marvel Comics universe, while another universe was designated as Earth-838. Sony's animated film Spider-Man: Across the Spider-Verse (2023) references the events of No Way Home, citing the MCU's primary reality as Earth-199999. 20th Century Fox's X-Men film series (2000–2020) is designated as Earth-10005 in Deadpool & Wolverine.
The histology of ALK-negative ALCL, similar to ALK-positive ALCL, consist of "hallmark" cells that strongly express CD30. Unlike ALK-positive ALCL, however, ALK-negative ALC does not fall into different morphological patterns. The histological of this disease may overlap with and be difficult to distinguish from other CD30-positive T-cell lymphomas or the nodular sclerosis form of Hodgkin lymphoma. Cases in which ALK-negative ALCL is not distinguishable from the latter lymphomas are best diagnosed as peripheral T-cell lymphoma not otherwise specified (PTL, NOS). The histology of ALK-negative ALCL may also overlap with tumors of non–T-cell lineage such as various carcinomas. The differential diagnoses of ambiguous cases may be helped by examining the tumor cells for the expression of certain marker proteins. For example, expression of CD56, MUC1 (also termed EMA for epithelial membrane antigen), and clusterin and strong uniform expression of CD30 support the diagnosis of ALK-negative ALCL over PTL, NOS, while variable CD30 expression and extensive expression of T-cell receptor proteins favor PTCL-NOS over ALK-negative ALCL. Detection of certain gene abnormalities (see next section) may also help distinguishing these diseases.
A significant amount of zirconium is formed by the fission process; some of this consists of short-lived radionuclides (95Zr and 97Zr which decay to molybdenum), while almost 10% of the fission products mixture after years of decay consists of five stable or nearly stable isotopes of zirconium plus 93Zr with a halflife of 1.53 million years which is one of the 7 major long-lived fission products. Zirconium is commonly used in cladding of fuel rods due to its low neutron cross section. However, a small share of this zirconium does capture neutrons and contributes to the overall inventory of radioactive zirconium isotopes. Zircalloy cladding is not commonly reused and neither is fission product zirconium, which could be used in cladding as its relatively weak radioactivity would be of no major concern inside a nuclear reactor. Despite its high yield and long live, Zr-93 is generally not deemed to be of major concern as it is not chemically mobile and emits little radiation. In PUREX plants the zirconium (regardless of source or isotope) sometimes forms a third phase which can be a disturbance in the plant. The third phase is the term in solvent extraction given to a third layer (such as foam and/or emulsion) which forms from the two layers in the solvent extraction process. The zirconium forms the third phase by forming small particles which stabilise the emulsion which is the third phase. Zirconium-90 mostly forms by successive beta decays out of strontium-90.
Sources: en.wikipedia.org
=== Bite treatment === First aid involves the application of an ice pack to control inflammation and prompt medical care. If it can be easily captured, the spider should be brought with the patient in a clear, tightly closed container so it may be identified by an arachnologist; if there is no specimen at all, then confirmation by an expert is impossible. Routine treatment should include immobilization of the affected limb, application of ice, local wound care, and tetanus prophylaxis. Many other therapies have been used with varying degrees of success, including hyperbaric oxygen, dapsone, antihistamines (e.g., cyproheptadine), antibiotics, dextran, glucocorticoids, vasodilators, heparin, nitroglycerin, electric shock, curettage, surgical excision, and antivenom. In almost all cases, bites are self-limited and typically heal without any medical intervention. Outpatient palliative care following discharge often consists of a weak or moderate strength opioid (e.g. codeine or tramadol, respectively) depending on pain scores, an anti-inflammatory agent (e.g. naproxen, cortisone), and an antispasmodic (e.g. cyclobenzaprine, diazepam), for a few days to a week. If the pain or spasms have not resolved by this time, a second medical evaluation is generally advised, and differential diagnoses may be considered.
== Awards and honors == United States National Academy of Sciences, member – 1942 Willard Gibbs Medal – 1943 American Philosophical Society, member – 1947 Albert Lasker Award for clinical medical research – 1952 American Academy of Arts and Sciences, member – 1953
=== Tt theoretical model === Oftentimes, ELPs are not used in isolation, but are rather fused with other proteins to become functionally active. The structure of these other proteins will have a certain effect on transition temperature. It is important to be able to predict the transition temperature that these fusion proteins will have relative to the free ELPs, as this temperature will determine the fused protein's applicability and phase transition. A theoretical model is available that relates the change in Tt of the fused protein to the varying ratios of each individual amino acid found in the fused protein. The model involves calculating a surface index (SI) associated with each amino acid and then extrapolating, based on the ratio of each amino acid present in the fused protein, the total change in the Tt associated with the fusion protein, ΔTt,fusion: SI=
=== Fourier transform ion cyclotron resonance mass spectrometry === FT- ICR EI - MS can be used for analysis of three vacuum gas oil (VGO) distillation fractions in 295-319 °C, 319-456 °C and 456-543 °C. In this method, EI at 10 eV allows soft ionization of aromatic compounds in the vacuum gas oil range. The compositional variations at the molecular level were determined from the elemental composition assignment. Ultra-high resolving power, small sample size, high reproducibility and mass accuracy (<0.4ppm) are the special features in this method. The major product was aromatic hydrocarbons in all three samples. In addition, many sulfur-, nitrogen-, and oxygen-containing compounds were directly observed when the concentration of this heteroatomic species increased with the boiling point. Using data analysis it gave the information about compound types (rings plus double bonds), their carbon number distributions for hydrocarbon and heteroatomic compounds in the distillation fractions, increasing average molecular weight (or carbon number distribution) and aromaticity with increasing boiling temperature of the petroleum fractions.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.
Yes. Stimulation of insulin secretion is glucose-dependent, meaning the effect is larger when blood glucose is high and minimal when it is normal. This property separates GLP-1 receptor agonists from agents that drive insulin release regardless of glucose level.
Receptor expression in hypothalamic and brainstem regions is well documented, and reduced energy intake is consistently observed. The relative contribution of central versus peripheral signaling to total weight change is still an open question addressed by ongoing research.
差别集中在三处：第 8 位残基被非天然氨基酸取代，第 34 位换成精氨酸，第 26 位增加一条脂肪酸侧链。前两处改动降低酶解速率，侧链则通过白蛋白结合延长循环时间。综合结果是半衰期从约两分钟延长到约一周。